Source: http://www.google.com/patents/US8106164?dq=6,455,937
Timestamp: 2016-05-05 13:43:30
Document Index: 464636960

Matched Legal Cases: ['Application No. 01945896', 'Application No. 07747965', 'Application No. 05753672', 'Application No. 07747965', 'Application No. 07747965', 'Application No. 08019830', 'Application No. 07747965', 'Application No. 07747965', 'Application No. 01945896', 'Application No. 01945896', 'Application No. 01945896', 'Application No. 01945896', 'Application No. 01945896', 'Application No. 07747965', 'Application No. 07747965', 'Application No. 200803655', 'Application No. 01945896']

Patent US8106164 - Antibodies specific for soluble amyloid beta peptide protofibrils and uses ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsThe invention pertains to the development of antibodies that specifically bind amyloid beta protein (Abeta) in its protofibril conformation. The invention also comprises methods of using anti-Abeta protofibril antibodies to diagnose or treat Alzheimer's disease, Down's syndrome Lewybody dementia, vascular...http://www.google.com/patents/US8106164?utm_source=gb-gplus-sharePatent US8106164 - Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereofAdvanced Patent SearchPublication numberUS8106164 B2Publication typeGrantApplication numberUS 11/570,995PCT numberPCT/SE2005/000993Publication dateJan 31, 2012Filing dateJun 21, 2005Priority dateJun 21, 2004Fee statusPaidAlso published asCA2570130A1, CA2570130C, EP1781703A1, EP1781703B1, US8404459, US8999936, US20090155246, US20120230912, US20130236452, US20150307601, WO2005123775A1Publication number11570995, 570995, PCT/2005/993, PCT/SE/2005/000993, PCT/SE/2005/00993, PCT/SE/5/000993, PCT/SE/5/00993, PCT/SE2005/000993, PCT/SE2005/00993, PCT/SE2005000993, PCT/SE200500993, PCT/SE5/000993, PCT/SE5/00993, PCT/SE5000993, PCT/SE500993, US 8106164 B2, US 8106164B2, US-B2-8106164, US8106164 B2, US8106164B2InventorsP�r Gellerfors, Lars LannfeltOriginal AssigneeBioarctic Neuroscience AbExport CitationBiBTeX, EndNote, RefManPatent Citations (84), Non-Patent Citations (290), Referenced by (15), Classifications (21), Legal Events (4) External Links: USPTO, USPTO Assignment, EspacenetAntibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
This application is the U.S. national stage filing under 35 U.S.C. �371 of international application PCT/SE2005/000993, filed Jun. 21, 2005, which claims benefit of Swedish Patent Application 0401601-0, filed Jun. 21, 2004.
A synthetic wtAβ31-40 peptide was dissolved in 1 volumes of 10 mM NaOH pH>10, and 1 volume of cold 2�PBS (pH 7-8) to a concentration of 50 uM. The wtAβ1-40 monomer preparation was centrifuged at 17.900�g at +4� C. for 5 minutes prior to analysis (FIG. 1).
A synthetic wtAβ1-42 peptide was dissolved in 9 volumes of 10 mM NaOH pH>10, vortexed for 2 minutes and diluted with 1 volume of 10�PBS (pH 7-8). The final peptide concentration was at this point 443 uM. The peptide was further incubated over night at 37� C. After the overnight incubation, the peptide was further diluted with PBS to 50 uM. The sample was centrifuged for 17.900�g for 5 minutes prior to analysis and immunisation.
A synthetic Aβ1-42Arc (E22G) peptide was dissolved in 1 volumes of 10 mM NaOH pH>10 and 1 volume cold 2�PBS (pH 7-8) to a final peptide concentration of 50 uM. The Aβ1-42Arc protofibrils were formed immediately and the Aβ1-42Arc protofibrils were stabilized by keeping the solution at 0-4� C. before analysis or immunization. The sample was centrifuged at 17.000�g for 5 minutes at +4� C. prior to analysis. Alternative ways to stabilize the Aβ1-42Arc protofibrils were to add glycerol to a final concentration of 5-50% or to add Tween-20 to a final concentration of 0.6%.
A synthetic wtAβ1-42 peptide was dissolved in 1 volumes of double distilled water, vortexed for 2 minutes and diluted with 1 volume of 2�PBS (pH 7-8) and vortexed again for 2 minutes. The final peptide concentration at this point was 50 uM. The wtAβ1-42 protofibril preparation was incubated at 37� C., for 48 hours before analysis. The sample was centrifuged at 17.900�g for 5 minutes prior to SEC analysis. The supernatant was analysed after centrifugation. No centrifugation was performed when Aβ1-42 fibril preparations were analysed by ELISA or dot blotting.
A Merck Hitachi D-7000 HPLC LaChrom system, having a diode array detector (DAD) model L-7455 and a model L-7100 pump, was used for the chromatographic analysis of protofibril preparations in combination with a Superdex 75 PC3.2/30 column (Amersham Pharmacia Biotech, Uppsala, Sweden). The chromatographic system separates Aβ monomers from protofibrils, which are eluting at the void volume of the column. The column was equilibrated with 50 mM Na2HPO4.NaH2PO4 (pH 7.4) with 0.15 M NaCl (PBS) and 0.6% Tween 20 and eluted with the same buffer at a flow rate of 0.08 ml/min (pressure was 5-6 bars) at ambient temperature (22� C.). Ten (10 ul) of a 50 uM-100 uM Aβ sample was subjected analysis using a wavelength scan between 200-400 nm. Tween-20 was added to the sample to give a final concentration of 0.6% prior to chromatography. Data was extracted from measurements at 214 and 280 nm. Peak areas were integrated using Merck Hitachi model D-7000 Chromatography Data Station Software. FIG. 1 shows chromatograms of wtAβ1-40 monomer, wtAβ1-42 protofibril, Aβ1-42Arc protofibril and wtAβ1-42 fibril preparations.
The specificity of mAb 258 was determined by a sandwich-ELISA. An 96-well ELISA plate was coated with mAb 258 over night at +4� C. After coating, wells were blocked with BSA for 1 hour at room temp. Aβ samples i.e wtAβ40 monomers, wtAβ42 protofibrils, wtAβ42-Arc protofibrils wtAβ42 fibrils, were added to the microtiterplate in 5� dilutions starting with 10 ug/ml. Samples were incubated for 1 hour at +4� C., after which 10 ng/well of a commercial secondary antibody, 6E10 (Signet) was added and incubated for 1 hour at room temp. Detection was achieved by incubation with a commercial ALP-conjugated anti-IgG antibody for 1 hour at room temp. and subsequent incubation with the substrate at room temp. for one hour according to the manufacturer's procedure. Samples were read in a microtiterplate reader (Spectra max 190 Molecular Devices, Sunyvale, USA) at 405 nm and 492 nm. FIG. 4A.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS5604102Oct 27, 1993Feb 18, 1997Athena Neurosciences, Inc.Methods of screening for β-amyloid peptide production inhibitorsUS5612486Nov 1, 1993Mar 18, 1997Athena Neurosciences, Inc.Transgenic animals harboring APP allele having swedish mutationUS5679531Jun 7, 1995Oct 21, 1997Bayer CorporationMethods of detecting βA4 peptide species ending at carboxy-terminus residue 42 using monoclonal antibody 369.2BUS5753624Aug 8, 1996May 19, 1998Milkhaus Laboratory, Inc.Materials and methods for treatment of plaquing diseaseUS5817626Mar 14, 1995Oct 6, 1998Praecis Pharmaceuticals IncorporatedModulators of beta-amyloid peptide aggregationUS5850003Jan 22, 1997Dec 15, 1998Athena NeurosciencesTransgenic rodents harboring APP allele having swedish mutationUS5851996Feb 13, 1998Dec 22, 1998Milkhaus Laboratory, Inc.Materials and methods for treatment of plaquing diseasesUS5854204Mar 14, 1996Dec 29, 1998Praecis Pharmaceuticals, Inc.Aβ peptides that modulate β-amyloid aggregationUS5854215Jun 7, 1995Dec 29, 1998Praecis Pharmaceuticals IncorporatedModulators of β-amyloid peptide aggregationUS5985242Aug 27, 1997Nov 16, 1999Praecis Pharmaceuticals, Inc.Modulators of β-amyloid peptide aggregation comprising D-amino acidsUS6054114May 7, 1997Apr 25, 2000Massachusetts Institute Of TechnologyOrganometallic ligands for the localization and quantification of amyloid in vivo and in vitroUS6114133Nov 14, 1994Sep 5, 2000Elan Pharmaceuticals, Inc.Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)US6174916Aug 8, 1997Jan 16, 2001Milkhaus Laboratory, Ltd.Methods for treating herpes virus infectionsUS6218506Feb 5, 1997Apr 17, 2001Northwestern UniversityAmyloid β protein (globular assembly and uses thereof)US6245964Dec 10, 1998Jun 12, 2001Elan Pharmaceuticals, Inc.Transgenic rodent comprising APP-SwedishUS6303567Aug 27, 1996Oct 16, 2001Praecis Pharmaceuticals, Inc .Modulators of β-amyloid peptide aggregation comprising D-amino acidsUS6319498Mar 14, 1996Nov 20, 2001Praecis Pharmaceuticals IncorporatedModulators of amyloid aggregationUS7179463Jul 9, 2001Feb 20, 2007Lars LannfeltTreatment of alzheimer's diseaseUS7427392Jun 6, 1995Sep 23, 2008Elan Pharmaceuticals, Inc.Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tauUS20020162129Jul 9, 2001Oct 31, 2002Lars LannfeltPrevention and treatment of alzheimer's diseaseUS20030068316Jun 11, 2002Apr 10, 2003Klein William L.Anti-ADDL antibodies and uses thereofUS20030187011Dec 17, 2002Oct 2, 2003Lashuel Hilal A.Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based diseaseUS20030232758Apr 10, 2003Dec 18, 2003Hospital For Sick Children And University Of TorontoImmunological methods and compositions for the treatment of Alzheimer's diseaseUS20040049134Jul 1, 2003Mar 11, 2004Tosaya Carol A.System and methods for treatment of alzheimer's and other deposition-related disorders of the brainUS20040170641Mar 31, 2004Sep 2, 2004Neuralab LimitedPrevention and treatment of amyloidogenic diseaseUS20040171815Nov 7, 2003Sep 2, 2004Schenk Dale B.Humanized antibodies that recognize beta amyloid peptideUS20040171816Nov 7, 2003Sep 2, 2004Schenk Dale B.Humanized antibodies that recognize beta amyloid peptideUS20050031629Mar 31, 2004Feb 10, 2005Neuralab LimitedPrevention and treatment of amyloidogenic diseaseUS20050124016Aug 2, 2004Jun 9, 2005Enh Research InstituteAntibodies specific for toxic amyloid beta protein oligomersUS20050142132Feb 14, 2005Jun 30, 2005Neuralab LimitedPrevention and treatment of amyloidogenic diseaseUS20050191314Apr 15, 2005Sep 1, 2005Neuralab LimitedPrevention and treatment of amyloidogenic diseaseUS20050249725Feb 27, 2004Nov 10, 2005Schenk Dale BHumanized antibodies that recognize beta amyloid peptideUS20060079447Oct 7, 2005Apr 13, 2006Wetzel Ronald BStabilized A-beta protofibrillar aggregatesUS20060166275May 16, 2005Jul 27, 2006Northwestern University & University Of Southern CaliforniaAmyloid beta protein (globular assembly and uses thereof)US20060178302Apr 6, 2005Aug 10, 2006Northwestern University & The University Of Southern CaliforniaAmyloid beta protein (globular assembly and uses thereof)US20060193850Jan 27, 2006Aug 31, 2006Warne Nicholas WAnti a beta antibody formulationUS20060228349Oct 21, 2005Oct 12, 2006Paul ActonAnti-ADDL antibodies and uses thereofUS20060240486Dec 15, 2005Oct 26, 2006Johnson-Wood Kelly LImmunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodiesUS20060280733Sep 12, 2003Dec 14, 2006The Regents Of The University Of CaliforniaImmunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequenceUS20070048312Jul 31, 2006Mar 1, 2007Klein William LAnti-ADDL antibodies and uses thereofUS20070081998Oct 17, 2006Apr 12, 2007Gene KinneyAnti-ADDL monoclonal antibody and use thereofUS20070098721Feb 2, 2004May 3, 2007Heinz HillenAmyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereofUS20070099185Nov 4, 2003May 3, 2007Bioarctic Neuroscience AbMethods for the identification of agents that modulate the structure and processing of beta-amyloid precursor proteinUS20070110750Sep 13, 2004May 17, 2007The Regents Of The University Of CaliforniaMonoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequenceUS20070148167Oct 17, 2006Jun 28, 2007Strohl William RNon-immunostimulatory antibody and compositions containing the sameUS20080181902Mar 19, 2008Jul 31, 2008Lars LannfeltPrevention and treatment of alzheimer's diseaseEP0783104A1Dec 17, 1996Jul 9, 1997Oriental Yeast Co., Ltd.Method for assaying soluble amyloid precursor proteinWO1991016819A1Mar 26, 1991Nov 14, 1991Molecular Rx., Inc.Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta proteinWO1995011994A1Oct 17, 1994May 4, 1995Athena Neurosciences, Inc.Methods of screening for beta-amyloid peptide production inhibitorsWO1995031996A1May 25, 1995Nov 30, 1995Milkhaus LabMaterials and methods for treatment of plaquing diseasesWO1996015452A1Nov 13, 1995May 23, 1996Athena Neurosciences, Inc.METHODS FOR AIDING IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE BY MEASURING AMYLOID-β PEPTIDE (X- ≥41) AND TAUWO1997041856A1May 7, 1997Nov 13, 1997Massachusetts Institute Of TechnologyORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO)WO1998033815A1Feb 5, 1998Aug 6, 1998Northwestern UniversityAmyloid beta protein (globular assembly and uses thereof)WO1999027944A1Nov 30, 1998Jun 10, 1999Neuralab LimitedPrevention and treatment of amyloidogenic diseaseWO1999027949A1Dec 3, 1998Jun 10, 1999Brigham And Women's HospitalMETHOD OF SUPPRESSING β-AMYLOID-RELATED CHANGES IN ALZHEIMER'S DISEASEWO2000039310A1Dec 29, 1999Jul 6, 2000The University Of Georgia Research Foundation, Inc.Rubredoxin fusion proteins, protein expression system and methodsWO2000071671A2May 26, 2000Nov 30, 2000New York UniversityNew mutant genes in familial british dementia and familial danish dementiaWO2000072870A1Jun 1, 2000Dec 7, 2000Neuralab, Ltd.Compositions of a-beta peptide and processes for producing sameWO2000072876A2Jun 1, 2000Dec 7, 2000Neuralab LimitedPrevention and treatment of amyloidogenic diseaseWO2000072880A2May 26, 2000Dec 7, 2000Neuralab LimitedPrevention and treatment of amyloidogenic diseaseWO2001010900A2Aug 4, 2000Feb 15, 2001University Of Southern CaliforniaGlobular assembly of amyloid beta protein and uses thereofWO2001039796A2Nov 29, 2000Jun 7, 2001Neurochem Inc.Vaccine for the prevention and treatment of alzheimer's and amyloid related diseasesWO2001090182A2May 22, 2001Nov 29, 2001New York UniversitySynthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid depositsWO2002003911A2Jul 5, 2001Jan 17, 2002Lars LannfeltPrevention and treatment of alzheimer's diseaseWO2003089460A1Apr 7, 2003Oct 30, 2003The Governing Council Of The University Of TorontoImmunological methods and compositions for the treatment of alzheimer's diseaseWO2003104437A2Jun 11, 2003Dec 18, 2003Northwestern UniversityAnti-addl antibodies and uses thereofWO2004024090A2Sep 12, 2003Mar 25, 2004The Regents Of The University Of CaliforniaImmunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequenceWO2004031400A2Oct 1, 2003Apr 15, 2004Northwestern UniversityAmyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereofWO2005019828A1Aug 20, 2004Mar 3, 2005Amorfix Life Sciences Ltd.Epitope protection assay and method for detecting protein conformationsWO2005025516A2Sep 13, 2004Mar 24, 2005The Regents Of The University Of CaliforniaMonoclonal antibodies specific for conformational epitopes of prefibrillar aggregatesWO2005089539A1Mar 17, 2005Sep 29, 2005Bioarctic Neuroscience AbTransgenic model for alzheimer’s diseaseWO2005123775A1Jun 21, 2005Dec 29, 2005Bioarctic Neuroscience AbAntibodies specific for soluble amyloid beta peptide protofibrils and uses thereofWO2006014478A1Jul 5, 2005Feb 9, 2006Northwestern UniversityMONOLOCAL ANTIBODIES THAT TARGET PATHOLOGICAL ASSEMBLIES OF AMYLOID β (ABETA)WO2006047254A1Oct 21, 2005May 4, 2006Regents Of The University Of MinnesotaAssemblies of oligomeric amyloid beta protein and uses thereofWO2006055178A2Oct 21, 2005May 26, 2006Merck & Co., Inc.Anti-addl antibodies and uses thereofWO2006066233A1Dec 15, 2005Jun 22, 2006Neuralab LimitedAn immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodiesWO2006083533A2Jan 17, 2006Aug 10, 2006The Regents Of The University Of CaliforniaCompositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disordersWO2006094724A2Mar 3, 2006Sep 14, 2006Abbott Gmbh & Co. KgScreening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodiesWO2006137354A1Jun 19, 2006Dec 28, 2006Medical & Biological Laboratories Co., Ltd.Antibody having inhibitory effect on amyloid fibril formationWO2007005358A2Jun 26, 2006Jan 11, 2007Merck & Co., Inc.Method for preparing a covalently cross linked oligomer of amyloid beta peptidesWO2007005359A1Jun 26, 2006Jan 11, 2007Merck & Co., Inc.Composition and method for producing stable amyloid beta oligomers of high molecular weightWO2007050359A2Oct 17, 2006May 3, 2007Merck & Co., Inc.Anti-addl monoclonal antibody and use thereofWO2007062088A1Nov 21, 2006May 31, 2007The Trustees Of The University Of PennsylvaniaAntibody treatment of alzheimer's and related diseasesWO2007108756A1Mar 23, 2007Sep 27, 2007Bioarctic Neuroscience AbImproved protofibril selective antibodies and the use thereofNon-Patent CitationsReference1Advisory Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Feb. 20, 2004.2Andreasen and Blennow, "Beta-amyloid (Abeta) Protein in Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease," Peptides 23:1205-1214, 2002.3Appellant's Statement of Grounds of Appeal together with a Main Request, First Auxiliary Request and Second Auxiliary Request for consideration by the Appeal Board, and a signed Declaration by Professor Dominic Walsh of the Conway Institute, Dublin, IE as filed in European Patent Application No. 01945896.7, Jan. 15, 2010.4Axelman et al., "A Large Swedish Family with Alzheimer's Disease with a Codon 670/671 Amyloid Precursor Protein Mutation," Arch. Neurol. 51:1193-1197, 1994.5Axelman, et al., "A Large Swedish Family with Alzheimer's Disease with a Codon 670/671 Amyloid Precursor Protein Mutation", Arch. Neurol., 51:1193-1197 (1994).6Bacskai et al., "Imaging of Amyloid-beta Deposits in Brains of Living Mice Permits Direct Observation of Clearance of Plaques with Immunotherapy," Nature Med. 7(3):369-372, 2001.7Bacskai et al., "Imaging of Amyloid-β Deposits in Brains of Living Mice Permits Direct Observation of Clearance of Plaques with Immunotherapy," Nature Med. 7(3):369-372, 2001.8Bard et al., "Peripherally Administered Antibodies Against Amyloid beta-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease," Nature Med. 6(8):916-919, 2000.9Bard et al., "Peripherally Administered Antibodies Against Amyloid β-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease," Nature Med. 6(8):916-919, 2000.10Bard, et al., "Peripherally administered antibodies against amyloid B-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease", Nature Medicine 6(8):916-919 (Aug. 2000).11Barghorn et al., "Globular Amyloid beta-Peptide Oligomer: A Homogenous and Stable Neuropathological Protein in Alzheimer's Disease," J. Neurochem. 95:834-47, 2005.12Barghorn et al., "Globular Amyloid β-Peptide Oligomer: A Homogenous and Stable Neuropathological Protein in Alzheimer's Disease," J. Neurochem. 95:834-47, 2005.13Bayer et al., "Evaluation of the Safety and Immunogenicity of Synthetic Abeta42 (AN1792) in Patients with AD," Neurology 64:94-101, 2005.14Bayer et al., "Evaluation of the Safety and Immunogenicity of Synthetic Aβ42 (AN1792) in Patients with AD," Neurology 64:94-101, 2005.15Bitan et al., "Amyloid beta-Protein (Abeta) Assembly: Abeta40 and Abeta42 Oligomerize Through Distinct Pathways," Proc. Natl. Acad. Sci. U.S.A. 100:330-5, 2003.16Bitan et al., "Amyloid β-Protein (Aβ) Assembly: Aβ40 and Aβ42 Oligomerize Through Distinct Pathways," Proc. Natl. Acad. Sci. U.S.A. 100:330-5, 2003.17Blanchard et al., "Efficient Reversal of Alzheimer's Disease Fibril Formation and Elimination of Neurotoxicity by a Small Molecule," Proc. Natl. Acad. Sci. U.S.A. 101(40):14326-32, 2004.18Cai et al., "Release of Excess Amyloid beta-Protein from a Mutant Amyloid beta-Protein Precursor," Science 259:514-516, 1993.19Cai et al., "Release of Excess Amyloid β-Protein from a Mutant Amyloid β-Protein Precursor," Science 259:514-516, 1993.20Cai, et al., "Release of Excess Amyloid b Protein from a Mutant Amyloid b Protein Precursor", Science, New Series, 259:514-516 (Jan. 22, 1993).21Caughey and Lansbury, "Protofibrils, Pores, Fibils, and Neurodegeneration: Separating the Responsible Protein Aggregates from the Innocent Bystanders," Ann. Rev. Neurosci. 26:267-98, 2003.22Chen et al., "A Learning Deficit Related to Age and beta-Amyloid Plaques in a Mouse Model of Alzheimer's Disease," Nature 408:975-978, 2000.23Chen et al., "A Learning Deficit Related to Age and β-Amyloid Plaques in a Mouse Model of Alzheimer's Disease," Nature 408:975-978, 2000.24Chromy et al., "Self-Assembly of Abeta1-42 Into Globular Neurotoxins," Biochemistry 42:12749-12760, 2003.25Chromy et al., "Self-Assembly of Aβ1-42 Into Globular Neurotoxins," Biochemistry 42:12749-12760, 2003.26Chromy et al., "Stability of Small Oligomers of Abeta1-42(ADDLs)," Society for Neuroscience 25:2129; 852.5, 1999.27Chromy et al., "Stability of Small Oligomers of Aβ1-42(ADDLs)," Society for Neuroscience 25:2129; 852.5, 1999.28Chromy, et al., "Self-Assembly of Aβ1-42 into Globular Neurotoxins", Biochemistry, 42:12749-12760 (2003).29Citron et al., "Mutant Presenilins of Alzheimer's Disease Increase Production of 42-Residue Amyloid beta-Protein in Both Transfected Cells and Transgenic Mice," Nature Med. 3(1):67-72, 1997.30Citron et al., "Mutant Presenilins of Alzheimer's Disease Increase Production of 42-Residue Amyloid β-Protein in Both Transfected Cells and Transgenic Mice," Nature Med. 3(1):67-72, 1997.31Citron et al., "Mutation of the beta-Amyloid Precursor Protein in Familial Alzheimer's Disease Increases beta-Protein Production," Nature 360:672-674, 1992.32Citron et al., "Mutation of the β-Amyloid Precursor Protein in Familial Alzheimer's Disease Increases β-Protein Production," Nature 360:672-674, 1992.33Citron, et al., "Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production", Nature, 360:672-674 (Dec. 17, 1992).34Communication as issued by European Patent Office regarding extended European Search Report for European Patent Application No. 07747965.7, dated May 13, 2009.35Communication from European Patent Application No. 05753672.4-2402, mailed Jul. 6, 2009.36Communication from European Patent Application No. 07747965.7, Nov. 17, 2009.37Communication of Notice of Opposition for European Patent Application No. 07747965.7, dated Oct. 13, 2011.38Conway et al., "Acceleration of Oligomerization, Not Fibrillization, is a Shared Property of Both alpha-Synuclein Mutations Linked to Early-Onset Parkinson's Disease: Implications for Pathogenesis and Therapy," Proc. Natl. Acad. Sci. U.S.A. 97(2):571-576, 2000.39Conway et al., "Acceleration of Oligomerization, Not Fibrillization, is a Shared Property of Both α-Synuclein Mutations Linked to Early-Onset Parkinson's Disease: Implications for Pathogenesis and Therapy," Proc. Natl. Acad. Sci. U.S.A. 97(2):571-576, 2000.40Dahlgren et al., "Oligomeric and Fibrillar Species of Amyloid-beta Peptides Differentially Affect Neuronal Viability," J. Biol. Chem. 277:32046-53, 2002.41Dahlgren et al., "Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability," J. Biol. Chem. 277:32046-53, 2002.42Dalfo et al., "Evidence of Oxidative Stress in the Neocortex in Incidental Lewy Body Disease," J. Neuropathol. Exp. Neurol. 64(9):816-830, 2005.43De Jonghe et al., "Flemish and Dutch Mutations in Amyloid beta Precursor Protein Have Different Effects on Amyloid beta Secretion," Neurobiol. Dis. 5:281-286, 1998.44De Jonghe et al., "Flemish and Dutch Mutations in Amyloid β Precursor Protein Have Different Effects on Amyloid β Secretion," Neurobiol. Dis. 5:281-286, 1998.45Declaration of P�r Gellerfors, dated Nov. 28, 2010.46Declaration Under Rule 132 (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Mar. 9, 2006.47DeMarco et al., "From Conversion to Aggregation: Protofibril Formation of the Prion Protein," Proc. Natl. Acad. Sci. U.S.A. 101:2293-2298, 2004.48DeMarco, et al., "From conversion to aggregation: Protofibril formation of the prion protein", PNAS., 101:2293-2298 (Feb. 24, 2004).49Dennis J. Selkoe, "Cell Biology of the Amyloid B-Protein Precursor and the Mechanism of Alzheimer's Disease", Annu. Rev. Cell Biol., 10:373-403 (1994).50Dennis J. Selkoe, "Normal and Abnormal Biology of the B-Amyloid Precursor Protein", Annu. Rev. Neurosci., 17:489-517 (1994).51Dodart et al., "Immunization Reverses Memory Deficits Without Reducing Brain Abeta Burden in Alzheimer's Disease Model," Nature Neurosci. 5:452-457, 2002.52Dodart et al., "Immunization Reverses Memory Deficits Without Reducing Brain Aβ Burden in Alzheimer's Disease Model," Nature Neurosci. 5:452-457, 2002.53Dodart, et al., "Immunization reverses memory deficits without reducing brain AB burden in alzheimer's disease model", Nature Neuroscience, 5:452-457 (May 2002).54El-Agnaf et al., "Oligomerization and Toxicity of β-Amyloid-42 Implicated in Alzheimer's Disease," Biochem. Biophys. Res. Comm. 273:1003-1007, 2000.55Enya et al., "Appearance of Sodium Dodecyl Sulfate-Stable Amyloid β-Protein (Aβ) Dimer in the Cortex During Aging," Am. J. Pathol. 154:271-279, 1999.56European Examination Report (EP 01 945 896.7), dated Apr. 24, 2007.57European Examination Report (EP 01 945 896.7), dated May 22, 2006.58European Examination Report (EP 01 945 896.7), dated Sep. 30, 2005.59Evidence D1-D6 included in Opposition Against European Patent No. 2,004,688 as filed by Acumen Pharmaceuticals dated Sep. 22, 2011.60Evidence D7-D11 included in Opposition Against European Patent No. 2,004,688 as filed by Acumen Pharmaceuticals dated Sep. 22, 2011.61Extended European Search Report for European Patent Application No. 08019830.2, May 31, 2010.62Extended European Search Report from European Patent Application No. 07747965.7, dated May 13, 2009.63Finder and Glockshuber, "Amyloid-β Aggregation," Neurodegener. Dis. 4(1):13-27, 2007.64Forsell et al., "Amyloid Precursor Protein Mutation at Codon 713 (Ala ->Val) Does Not Cause Schizophrenia: Non-Pathogenic Variant Found at Codon (Silent)," Neurosci. Lett. 184:90-93, 1995.65Forsell et al., "Amyloid Precursor Protein Mutation at Codon 713 (Ala →Val) Does Not Cause Schizophrenia: Non-Pathogenic Variant Found at Codon (Silent)," Neurosci. Lett. 184:90-93, 1995.66Frackowiak et al., "Non-Fibrillar β-Amyloid Protein is Associated with Smooth Muscle Cells of Vessel Walls in Alzheimer Disease," J. Neuropathol. Exp. Neurol. 53:637-645, 1994.67Frenkel et al, "Modulation of Alzheimer's Beta-amyloid Neurotoxicity by Site-directed Single-chain Antibody," J. Neuroimmunol. 106:23-31, 2000.68Frenkel et al, "Modulation of Alzheimer's Beta-amyloid Neurotoxicity by Site-directed Single-chain Antibody," Neuroimmunomodulation 6:444, 1999.69Frenkel et al., "Immunization Against Alzheimer's β-Amyloid Plaques Via EFRH Phage Administration," Proc. Natl. Acad. Sci. U.S.A. 97(21):11455-11459, 2000.70Giasson et al., "A Panel of Epitope-Specific Antibodies Detects Protein Domains Distributed Throughout Human Alpha-Synuclein in Lewy Bodies of Parkinson's Disease," J. Neurosci. Res. 59:528-533, 2000.71Giulian et al., "The HHQK Domain of β-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," J. Biol. Chem. 273(45):29719-29726, 1998.72Glenner et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," Biochem. Biophys. Res. Comm. 120(3):885-890, 1984.73Glenner, et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein", Biochemical and Biophysical Research Communications, 120(3):885-890 (1984).74Golabek et al., "The Interaction between Apolipoprotein E and Alzheimer's Amyloid β-Peptide Is Dependent on β-Peptide Conformation," J. Biol. Chem. 271(18):10602-10606, 1996.75Grabowski et al., "Novel Amyloid Precursor Protein Mutation in an Iowa Family with Dementia and Severe Cerebral Amyloid Angiopathy," Ann. Neurol. 49:697-705, 2001.76Guerette et al., "Oligomeric Aβ in PBS-Soluble Extracts of Human Alzheimer Brain," Society for Neuroscience 25:2129; 852.1, 1999.77Hardy, "Amyloid, the Presenilins and Alzheimer's Disease," Trends Neurosci. 20(4):154-159, 1997.78Hardy, "Framing β-Amyloid," Nature Genet. 1:233-234, 1992.79Harley, et al., "Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons", The Journal of Neuroscience, 19(20):8876-8884 (Oct. 15, 1999).80Harper et al., "Assembly of Aβ Amyloid Protofibrils: An In Vitro Model for a Possible Early Event in Alzheimer's Disease," Biochemistry 38:8972-8980, 1999.81Harper et al., "Observation of Metastable Aβ Amyloid Protofibrils by Atomic Force Microscopy," Chem. Biol. 4:119-125, 1997.82Hartley et al., "Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons," J. Neurosci. 19(20):8876-8884, 1999.83Hendriks et al., "Presenile Dementia and Cerebral Hemorrhage Linked to a Mutation at Codon 692 of the β-Amyloid Precursor Protein Gene," Nature Genet. 1:218-221, 1992.84Hock and Nitsch, "Clinical Observations with AN-1792 Using TAPIR Analyses," Neurodegener Dis. 2:273-276, 2005.85Hoshi et al., "Spherical Aggregates of β-Amyloid (Amylospheroid) Show High Neurotoxicity and Activate Tau Protein Kinase I/glycogen Synthase Kinase-3β," Proc. Natl. Acad. Sci. U.S.A. 100(11):6370-6375, 2003.86Hoshi, et al., "Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β", PNAS, 100(11):6370-6375 (May 27, 2003).87International Preliminary Report (PCT/US2003/30930), completed Feb. 6, 2006.88International Preliminary Report on Patentability (PCT/SE01/01553), completed Oct. 23, 2002.89International Preliminary Report on Patentability (PCT/SE05/000993), issued Dec. 28, 2006.90International Preliminary Report on Patentability (PCT/SE07/000292), issued Sep. 23, 2008.91International Preliminary Report on Patentability (PCT/US2003/19640), completed Aug. 7, 2006.92International Search Report (PCT/SE01/01553), mailed Feb. 4, 2002.93International Search Report (PCT/SE05/000993), mailed Oct. 4, 2005.94International Search Report (PCT/SE07/000292), mailed Jul. 20, 2007.95Interview Summary (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), dated Oct. 21, 2003.96Invitation Pursuant to Article 94(3) and Rule 71(1) EPC from European Patent Application No. 07747965.7-1222, Mar. 26, 2010.97Isaacs et al., "Acceleration of Amyloid β-Peptide Aggregation by Physiological Concentrations of Calcium," J. Biol. Chem. 281(38):27916-23, 2006.98Janus et al., "A β Peptide Immunization Reduces Behavioral Impairment and Plaques in a Model of Alzheimer's Disease," Nature 408:979-982, 2000.99Janus, et al., "Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease", Nature, 408:979-982 (Dec. 2000).100Jensen et al., "Quantification of Alzheimer Amyloid beta Peptides Ending at Residues 40 and 42 by Novel ELISA Systems," Mol. Med. 6:291-302, 2000.101Jensen et al., "Quantification of Alzheimer Amyloid β Peptides Ending at Residues 40 and 42 by Novel ELISA Systems," Mol. Med. 6:291-302, 2000.102Johansson et al., "Physiochemical Characterization of the Alzheimer's Disease-Related Peptides Abeta1-42 Arctic and Abeta1-42 wt" FEBS J. 273:2618-2630, 2006.103Johansson et al., "Physiochemical Characterization of the Alzheimer's Disease-Related Peptides Aβ1-42 Arctic and Aβ1-42 wt" FEBS J. 273:2618-2630, 2006.104John Hardy, "Framing β-amyloid", Nature Genetics, 1:233-234 (Jul. 1992).105Johnston et al., "Increased beta-Amyloid Release and Levels of Amyloid Precursor Protein (APP) in Fibroblast Cell Lines From Family Members With the Swedish Alzheimer's Disease APP670/671 Mutation," FEBS Lett. 354:274-278, 1994.106Johnston et al., "Increased β-Amyloid Release and Levels of Amyloid Precursor Protein (APP) in Fibroblast Cell Lines From Family Members With the Swedish Alzheimer's Disease APP670/671 Mutation," FEBS Lett. 354:274-278, 1994.107Johnston, et al., "Increased β-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670/671 mutation", FEBS Letters, 354:274-278 (1994).108Kamino et al., "Linkage and Mutational Analysis of Familial Alzheimer Disease Kindreds for the APP Gene Region," Am. J. Hum. Genet. 51:998-1014, 1992.109Kang et al., "The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-surface Receptor," Nature 325:733-736, 1987.110Kayed et al., "Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis," Science 300:486-489, 2003.111Kayed et al., "Immunization With a Molecular Mimic of a Toxic Aggregates Generates a Conformation-Dependent Antibody Specific for High Molecular Weight A Aggregates (Micelles and Protofibrils)," 32nd Annual Meeting of the Society for Neuroscience, Orlando, Florida (Society for Neuroscience Abstract Viewer and Itinerary Planner, Abstract No. 685.3, 2002).112Kayed, et al., "Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis", Science, 300:486-489 (Apr. 18, 2003).113Kirkitadze et al., "Paradigm Shifts in Alzheimer's Disease and Other Neurodegenerative Disorders: The Emerging Role of Oligomeric Assemblies," J. Neurosci. Res. 1, 69:567-77, 2002.114Klafki et al., "Therapeutic Approaches to Alzheimer's Disease," Brain 129:2840-2855, 2006.115Klein et al., "Oligemia-Induced Expression of c-fos and Oxidative Stress-Related Protein in the Murine Brain," 30th Annual Meeting of the Society of Neuroscience, New Orleans, LA, Nov. 4-9, 2000, Soc. Neurosci. Abstracts 26(1-2), Abstract 383.15, 2000.116Klein et al., "Oligomer/Conformation-Dependent Aβ Antibodies," Soc. Neurosci. Abstr. Presentation No. 475.11, Tuesday Nov. 7, 2000.117Klein et al., "Targeting Small Aβ Oligomers: The Solution to an Alzheimer's Disease Conundrum?" Trends Neurosci. 24:219-224, 2001.118Klein, "Aβ Toxicity in Alzheimer's Disease," Contemporary Clinical Neuroscience: Molecular Mechanisms of Neurodegenerative Diseases 1.1 Introduction, 2001.119Klyubin et al., "Inhibitory Effect of Amyloid-beta Peptide with the Arctic Mutation on Long-term Potentiation in Area CA1 of Rat Hippocampus In Vivo," J. Physiol. 551P, C32, 2003.120Klyubin et al., "Inhibitory Effect of Amyloid-β Peptide with the Arctic Mutation on Long-term Potentiation in Area CA1 of Rat Hippocampus In Vivo," J. Physiol. 551P, C32, 2003.121Klyubin et al., "Soluble Arctic Amyloid β Protein Inhibits Hippocampal Long-Term Potentiation In Vivo," Eur. J. Neurosci. 19:2839-2846, 2004.122Klyubin, et al., "Soluble Arctic amyloid β protein inhibits hippocampal long-term potentiation in vivo", European Journal of Neuroscience, 19:2839-2846 (2004).123Kuo et al., "Water-soluble Aβ (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," J. Biol. Chem. 271:4077-4081, 1996.124Lambert et al., "Diffusible, Nonfibrillar Ligands Derived From Aβ1-42 Are Potent Central Nervous System Neurotoxins," Proc. Natl. Acad. Sci. U.S.A. 95:6448-6453, 1998.125Lambert et al., "Monoclonal Antibodies that Target Pathological Assemblies of Aβ," J. Neurochem. 100:23-35, 2007.126Lambert et al., "Neuron Dysfunction and Death Caused by Small Aβ Oligomers: Role of Signal Transduction," Society for Neuroscience 25:2129, 1999.127Lambert et al., "Vaccination With Soluble Aβ Oligomers Generates Toxicity-Neutralizing Antibodies," J. Neurochem. 79:595-605, 2001.128Lambert, et al., "Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins", Proc. Natl. Acad. Sci. USA, 95:6448-6453 (May 1998).129Lambert, et al., "Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies", Journal of Neurochemistry, 79:595-605 (2001).130Lannfelt et al., "Amyloid beta-Peptide in Cerebrospinal Fluid in Individuals with the Swedish Alzheimer Amyloid Precursor Protein Mutation," Neurosci. Lett. 199:203-206, 1995.131Lannfelt et al., "Amyloid Precursor Protein Mutation Causes Alzheimer's Disease in a Swedish Family," Neurosci. Lett. 168:254-256, 1994.132Lannfelt et al., "Amyloid β-Peptide in Cerebrospinal Fluid in Individuals with the Swedish Alzheimer Amyloid Precursor Protein Mutation," Neurosci. Lett. 199:203-206, 1995.133Lannfelt et al., "Genetics of Alzheimer's Disease-Routes to the Pathophysiology," J. Neural. Transm. [Suppl.] 59:155-161, 2000.134Lannfelt et al., "Genetics of Alzheimer's Disease—Routes to the Pathophysiology," J. Neural. Transm. [Suppl.] 59:155-161, 2000.135Lannfelt et al., "Genetics, Pathophysiology and Abeta Protofibril Formation in Alzheimer's Disease," Neurobiol. Aging 25(Suppl. 2): Poster Session P2: Epidemiology and Risk Factors of Alzheimer's Disease P2-268; S308, 2004.136Lannfelt et al., "Genetics, Pathophysiology and Aβ Protofibril Formation in Alzheimer's Disease," Neurobiol. Aging 25(Suppl. 2): Poster Session P2: Epidemiology and Risk Factors of Alzheimer's Disease P2-268; S308, 2004.137Lannfelt et al., "Monoclonal Antibodies Selective for Abeta Protofibrils Reduce Plaque Sensitive Detection of Alzheimer Abeta Protofibrils by Burden in Transgenic Mice Models of Alzheimer's Disease Conformation Specific ELISA," ICAD meeting, Uppsala University, Sweden, Jul. 16, 2006.138Lannfelt et al., "Monoclonal Antibodies Selective for Abeta Protofibrils: Detection of Protofibrils and Reduction of Plaque Burden in Tg-mice Models of Alzheimer's Disease," SfN meeting, Uppsala University, Sweden, Oct. 17, 2006.139Lannfelt et al., "Monoclonal Antibodies Selective for Aβ Protofibrils Reduce Plaque Sensitive Detection of Alzheimer Aβ Protofibrils by Burden in Transgenic Mice Models of Alzheimer's Disease Conformation Specific ELISA," ICAD meeting, Uppsala University, Sweden, Jul. 16, 2006.140Lannfelt et al., "Monoclonal Antibodies Selective for Aβ Protofibrils: Detection of Protofibrils and Reduction of Plaque Burden in Tg-mice Models of Alzheimer's Disease," SfN meeting, Uppsala University, Sweden, Oct. 17, 2006.141Lannfelt, et al., "Amyloid Precursor Protein Mutation Causes Alzheimer's Disease in a Swedish Family", Neuroscience Letters, 168:254-256 (1994).142Lannfelt, et al., "Amyloid β-peptide in Cerebrospinal Fluid in Individuals with the Swedish Alzheimer Amyloid Precursor Protein Mutation", Neuroscience Letters, 199:203-206 (1995).143Lashuel et al., "Mixtures of Wild-Type and a Pathogenic (E22G) Form of Aβ40 In Vitro Accumulate Protofibrils, Including Amyloid Pores," J. Mol. Biol. 332:795-808, 2003.144Lashuel, et al., "Mixtures of Wild-type and a Pathogenic (E22G) Form of Aβ40 in Vitro Accumulate Protofibrils, Including Amyloid Pores", J. Mol. Biol., 332:795-808 (2003).145Lee et al., "Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice," J. Biol. Chem. 2006 281:4292-4299.146Levy et al., "Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type," Science 248:1124-1126, 1990.147Liu et al., "Residues 17-20 and 30-35 of β-Amyloid Play Critical Roles in Aggregation," J. Neurosci. Res. 75(2):162-71, 2004.148Longo and Finch, "Nonfibrillar Aβ 1-42 (ADDL) Causes Aconitase Inactivation and Iron-dependent Neurotoxicity," Society for Neuroscience 25: 2129, 1999.149Masters et al., "Amyloid Plaque Core Protein in Alzheimer's Disease and Down Syndrome," Proc. Natl. Acad. Sci. U.S.A. 82:4245-4249, 1985.150Masters, et al., "Amyloid Plaque Core Protein in Alzheimer Disease and Down Syndrome", PNAS, 82:4245-4249 (1985).151McKhann et al., "Clinical Diagnosis of Alzheimer's Disease: Report of the NINCHS-ADRDA Work Group Under the Auspices of Department of Health and Human Services Task Force on Alzheimer's Disease," Neurology 34:939-944, 1994.152McKhann, et al., "Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease", Neurology, 34:939-944 (Jul. 1994).153Minutes from Oral Proceedings for European Patent Application No. 01945896.7-2402, dated Dec. 17, 2008.154Miravelle et al., "Substitutions at Codon 22 of Alzheimer's Aβ Peptide Induce Diverse Conformational Changes and Apoptotic Effects in Human Cerebral Endothelial Cells," J. Biol. Chem. 275:27110-27116, 2000.155Morgan et al., "Aβ Peptide Vaccination Prevents Memory Loss in an Animal Model of Alzheimer's Disease," Nature 408:982-985, 2000.156Morgan, et al., "AB peptide vaccination prevents memory loss in an animal model of Alzheimer's disease", Nature, 408:982-985 (Dec. 2000).157Moss et al., "The Peptide KLVFF-K6 Promotes β-Amyloid(1-40) Protofibril Growth by Association but Does Not Alter Protofibril Effects on Cellular Reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT)," Mol. Pharmacol. 64(5):1160-8, 2003.158Motter et al., "Reduction of β-Amyloid Peptide42 in the Cerebrospinal Fluid of Patients with Alzheimer's Disease," Ann. Neurol. 38:643-648, 1995.159Motter, et al., "Reduction of B-Amyloid Peptide42 in the Cerebrospinal Fluid of Patients with Alzheimer's Disease", Ann. Neurol., 38:643-648 (1995).160Mullan et al., "A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-terminus of beta-Amyloid," Nature Genet. 1:345-347, 1992.161Mullan et al., "A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-terminus of β-Amyloid," Nature Genet. 1:345-347, 1992.162Mullen, et al., "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid", Nature Genetics, 1:345-347 (Aug. 1992).163Nichols et al., "Amyloid-β Aggregates Formed at Polar-Nonpolar Interfaces Differ From Amyloid-β Protofibrils Produced in Aqueous Buffers," Microsc. Res. Tech. 67(3-4):164-74, 2005.164Nichols et al., "Growth of beta-amyloid(1-40) Protofibrils by Monomer Elongation and Lateral Association. Characterization of Distinct Products by Light Scattering and Atomic Force Microscopy," Biochemistry 41(19):6115-6127, 2002.165Nichols et al., "Growth of β-amyloid(1-40) Protofibrils by Monomer Elongation and Lateral Association. Characterization of Distinct Products by Light Scattering and Atomic Force Microscopy," Biochemistry 41(19):6115-6127, 2002.166Nicoll et al., "Neuropathology of Human Alzheimer Disease After Immunization With Amyloid-β Peptide: A Case Report," Nature Med. 9(4):448-452, 2003.167Nicoll, et al., "Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report", Nature Medicine, 9:4:448-452 (Apr. 2003).168Nilsberth et al., "A Novel APP Mutation (E693G)—The Arctic Mutation Causing Alzheimer's Disease with Vascular Symptoms," Soc. Neurosci. Abstr. 25:297; 1999.169Nilsberth et al., "A Novel APP Mutation (E693G)-The Arctic Mutation, Causing, Alzheimer's Disease with Vascular Symptoms," Society for Neuroscience Annual Meeting, Miami Beach, Abstract, 120.4; Nov. 1999.170Nilsberth et al., "A Novel APP Mutation (E693G)—The Arctic Mutation, Causing, Alzheimer's Disease with Vascular Symptoms," Society for Neuroscience Annual Meeting, Miami Beach, Abstract, 120.4; Nov. 1999.171Nilsberth et al., "The ‘Arctic’ APP Mutation (E693G) Causes Alzheimer's Disease by Enhanced Aβ Protofibril Formation," Nature Neurosci. 4(9):887-893, 2001.172Nilsberth et al., "The ‘Arctic’ APP Mutation (E693G) Causes Alzheimer's Disease by Enhanced Aβ Protofibril Formation," Neurobiology of Aging, May-Jun. 2000, 21, Abstract 265, Supplement 1, 1-304.173Nilsberth et al., "The 'Arctic' APP Mutation (E693G) Causes Alzheimer's Disease by Enhanced Abeta Protofibril Formation," Nature Neurosci. 4(9):887-893, 2001.174Nilsberth et al., "The 'Arctic' APP Mutation (E693G) Causes Alzheimer's Disease by Enhanced Abeta Protofibril Formation," Neurobiology of Aging, May-Jun. 2000, 21, Abstract 265, Supplement 1, 1-304.175Nilsberth et al., "The Attic APP Mutation (E693G) Causes Alzheimer's Disease Through a Novel Mechanism: Increased Amyloid beta Protofibril Formation and Decreased Amyloid beta Levels in Plasma and Conditioned Media," Neurobiol. Aging 21:S58, 2000.176Nilsberth et al., "The Attic APP Mutation (E693G) Causes Alzheimer's Disease Through a Novel Mechanism: Increased Amyloid β Protofibril Formation and Decreased Amyloid β Levels in Plasma and Conditioned Media," Neurobiol. Aging 21:S58, 2000.177Nilsberth, et al., "The ‘Arctic’ APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation", Nature Neuroscience, 4(9):887-893 (2001).178Notice of Allowance (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Oct. 16, 2006.179Notice of Appeal (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Nov. 25, 2003.180Notice of intent to grant a European patent and Annex (Reasons for Decision) (EP 01 945 896.7), dated Mar. 18, 2009.181Notice of Opposition to a European Patent for European Patent No. 2,004,688 as filed by Acumen Pharmaceuticals, dated Sep. 22, 2011.182Oda et al., "Clusterin (apoJ) Alters the Aggregation of Amyloid β-Peptide (Aβ 1-42) and Forms Slowly Sedimenting Aβ Complexes that Cause Oxidative Stress," Exp. Neurol. 136:22-31, 1995.183Oda et al., "Purification and Characterization of Brain Clusterin," Biochem. Biophys. Res. Comm. 204:1131-6, 1994.184Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463) mailed May 8, 2006.185Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Jul. 7, 2005.186Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Jun. 25, 2003.187Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Nov. 19, 2002.188Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Nov. 24, 2004.189Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Nov. 9, 2005.190O'Nuallain et al., "Conformational Abs Recognizes a Generic Amyloid Fibril Epitope," Proc. Natl. Acad. Sci. U.S.A. 99:1485-1490, 2002.191O'Nuallain, et al., "Conformational Abs recognizing a generic amyloid fibril epitope", PNAS., 99:1485-1490 (Feb. 5, 2002).192Opposition Against European Patent No. 2,004,688 as filed by Acumen Pharmaceuticals dated Sep. 22, 2011, including (1) Facts and arguments in support of opposition: Annex 1; (2) Annex 2.193P�ivi� et al., "Unique Physicochemical Profile of beta-Amyloid Peptide Variant Abeta1-40E22G Protofibrils: Conceivable Neuropathogen in Arctic Mutant Carriers," J. Med. Biol. 339:145-159, 2004.194P�ivi� et al., "Unique Physicochemical Profile of β-Amyloid Peptide Variant Aβ1-40E22G Protofibrils: Conceivable Neuropathogen in Arctic Mutant Carriers," J. Med. Biol. 339:145-159, 2004.195Palmert et al., "The β-Amyloid Protein Precursor of Alzheimer Disease Has Soluble Derivatives Found in Human Brain and Cerebrospinal Fluid," Proc. Natl. Acad. Sci. U.S.A. 86:6338-6342, 1989.196Pirttil� et al., "Soluble Amyloid β-Protein in the Cerebrospinal Fluid From Patients with Alzheimer's Disease, Vascular Dementia and Controls," J. Neurol. Sci. 127:90-95, 1994.197Pirttil�, et al., "Soluble amyloid β-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls", Journal of the Neurological Science, 127:90-95 (1994).198Ponte et al., "A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors," Nature 331:525-527, 1988.199Qin et al., "Effect of 4-Hydroxy-2-Nonenal Modification on Alpha-Synuclein Aggregation," J. Biol. Chem. 282(8):5862-5870, 2007.200Reply to Examination Report (European Patent Application No. 01945896.7-2402), mailed Apr. 7, 2006.201Reply to Examination Report (European Patent Application No. 01945896.7-2402), mailed Nov. 5, 2007.202Reply to Examination Report (European Patent Application No. 01945896.7-2402), mailed Sep. 22, 2006.203Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Apr. 21, 2003.204Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Aug. 8, 2006.205Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Dec. 18, 2003.206Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Mar. 24, 2005.207Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Mar. 9, 2006.208Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Oct. 7, 2005.209Reply to Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Sep. 10, 2004.210Reply to Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Sep. 3, 2002.211Request for Continued Examination (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Mar. 25, 2004.212Request Pursuant to Oral Proceedings (European Patent Application No. 01945896.7-2402), mailed Oct. 10, 2008.213Response to Communication in European Patent Application No. 07747965.7-1222, Jan. 29, 2010.214Response to Communication in European Patent Application No. 07747965.7-1222, Sep. 11, 2009.215Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Jul. 3, 2002.216Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), mailed Jun. 10, 2004.217Resubmission of Reply to Office Action (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Feb. 3, 2004.218Roher et al., "Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease," J. Biol. Chem. 271:20631-20635, 1996.219Russo et al., "Presenilin-1 Mutations in Alzheimer's Disease," Nature 405:531-532, 2000.220Rzepecki et al., "Prevention of Alzheimer's Disease-Associated Aβ Aggregation by Rationally Designed Nonpeptitdic β-Sheet Ligands," J. Biol. Chem. 279:47497-47505, 2004.221Sahlin et al., "The Arctic Alzheimer Mutation Favors Intracellular Amyloid-beta Production by Making Amyloid Precursor Protein Less Available to alpha -secretase," J. Neurochem. 101:854-862, 2007.222Sahlin et al., "The Arctic Alzheimer Mutation Favors Intracellular Amyloid-β Production by Making Amyloid Precursor Protein Less Available to α -secretase," J. Neurochem. 101:854-862, 2007.223Schenk et al., "Immunization with Amyloid-β Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse," Nature 400:173-177, 1999.224Schenk et al., "Immunization with Amyloid-β Attenuates Alzheimer-Disease-Like Pathology in the PDAPP," Nature 400:173-177, 1999.225Scheuner et al., "Secreted Amyloid beta-Protein Similar to That in the Senile Plaques of Alzheimer's Disease is Increased In Vivo by the Presenilin 1 and 2 and APP Mutations Linked to Familial Alzheimer's Disease," Nature Med. 2(8):864-870, 1996.226Scheuner et al., "Secreted Amyloid β-Protein Similar to That in the Senile Plaques of Alzheimer's Disease is Increased In Vivo by the Presenilin 1 and 2 and APP Mutations Linked to Familial Alzheimer's Disease," Nature Med. 2(8):864-870, 1996.227Scheuner, et al., "Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease", Nature Medicine, 2(8):864-870 (Aug. 1996).228Search Report and Written Opinion as issued by Intellectual Property Office of Singapore regarding Singapore Patent Application No. 200803655-0, dated Oct. 8, 2009.229Selkoe, "Cell Biology of the Amyloid β-Protein Precursor and the Mechanism of Alzheimer's Disease," Ann. Rev. Cell Biol. 10:373-403, 1994.230Selkoe, "Normal and Abnormal Biology of the β-Amyloid Precursor Protein," Ann. Rev. Neurosci. 17:489-517, 1994.231Serpell, "Alzheimer's Amyloid Fibrils: Structure and Assembly," Biochim. Biophys. Acta 1502:16-30, 2000.232Seubert et al., "Isolation and Quantification of Soluble Alzheimer's β-Peptide From Biological Fluids," Nature 359:325-327, 1992.233Seubert, et al., "Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids", Nature, 359:325-327 (Sep. 1992).234Sherrington et al., "Cloning of a Gene Bearing Missense Mutations in Early-Onset Familial Alzheimer's Disease," Nature 375:754-760, 1995.235Shtilerman et al., "Molecular Crowding Accelerates Fibrillization of α-Synuclein: Could an Increase in the Cytoplasmic Protein Concentration Induce Parkinson's Disease?" Biochemistry 41:3855-3860, 2002.236Shtilerman, et al., "Molecular Crowding Accelerates Fibrillization of a-Synuclein: Could an Increase in the Cytoplasmic Protein Concentration Induce Parkinson's Disease?", Biochemistry, 41:3855-3860 (2002).237Sigurdsson et al., "Immunization With a Nontoxic/Nonfibrillar Amyloid-β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice," Am. J. Pathol. 159(2):439-447, 2001.238Sigurdsson, et al., "Immunization with a Nontoxic/Nonfibrillar Amyloid-β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice", American Journal of Pathology, 159:2:439-447 (Aug. 2001).239Solomon et al., "Disaggregation of Alzheimer β-amyloid by Site-directed mAb," Proc. Natl. Acad. Sci. U.S.A. 94:4109-4112, 1997.240Solomon et al., "Monoclonal Antibodies Inhibit In Vitro Fibrillar Aggregation of the Alzheimer Beta-amyloid Peptide," Proc. Natl. Acad. Sci. U.S.A. 93:452-455, 1996.241Solomon et al., "Monoclonal Antibodies Restore and Maintain the Soluble Conformation of β-amyloid Peptide," Neurobiol. Aging, vol. 17, No. 4, Suppl. 152, 1996.242Soto et al., "The Conformation of Alzheimer's β Peptide Determines the Rate of Amyloid Formation and Its Resistance to Proteolysis," Biochem. J. 1:314:701-7, 1996.243Soto et al., "The Conformation of Alzheimer's β Peptide Determines the Rate of Amyloid Formation and Its Resistance to Proteolysis," Biochem. J. 1:314:701-707, 1996.244Srinivasan et al., "ABri Peptide Associated with Familial British Dementia Forms Annular and Ring-Like Protofibrillar Structures," Amyloid 11(1):10-3, 2004.245St. George-Hyslop et al., "Genetic Linkage Studies Suggest that Alzheimer's Disease is Not a Single Homogeneous Disorder," Nature 347:194-197, 1990.246St. George-Hyslop et al., "The Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21," Science 235:885-890, 1987.247Stenh et al., "Amyloid-beta Oligomers are Inefficiently Measured by Enzyme-Linked Immunosorbent Assay," Ann. Neurol. 58: 147-150, 2005.248Stenh et al., "Amyloid-β Oligomers are Inefficiently Measured by Enzyme-Linked Immunosorbent Assay," Ann. Neurol. 58: 147-150, 2005.249Stenh et al., "The Arctic Mutation Interferes with Processing of the Amyloid Precursor Protein," NeuroReport 13: 1857-1860, 2002.250Stine et al., "Supramolecular Structures of Aβ Aggregates and Cellular Responses," Biophysical Journal Program and Abstracts:40th Annual Meeting Feb. 17-21, 1996, Biophys J. 70: Abstract 239.251Stine et al., "The Nanometer-Scale Structure of Amyloid-β Visualized by Atomic Force Microscopy," J. Prot. Chem. 15(2):193-203, 1996.252Stine, et al., "The Nanometer-Scale Structure of Amyloid-β Visualized by Atomic Force Microscopy", Journal of Protein Chemistry, 15:2:193-203 (1996).253Summons to Attend Oral Proceedings (European Patent Application No. 01945896.7-2402), dated Jul. 25, 2008.254Supplemental Reply to Restriction Requirement (U.S. Appl. No. 09/899,815; U.S. Patent No. 7,179,463), filed Sep. 21, 2004.255Suzuki et al., "An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βAPP717) Mutants," Science 264:1336-1340, 1994.256Tagliavani et al., "A New betaAPP Mutation Related to Hereditary Cerebral Haemorrhage," Alz. Report 2(Suppl. 1):S28, Abstract 23, 1999.257Tagliavani et al., "A New βAPP Mutation Related to Hereditary Cerebral Haemorrhage," Alz. Report 2(Suppl. 1):S28, Abstract 23, 1999.258U.S. Appl. No. 09/369,236, filed Aug. 4, 1999, Krafft et al.259U.S. Appl. No. 09/745,057, filed Dec. 20, 2000, Krafft et al.260U.S. Appl. No. 10/166,856, filed Jun. 11, 2002, Klein et al.261U.S. Appl. No. 11/570,995, filed Dec. 20, 2006, Gellerfors et al.262U.S. Appl. No. 12/294,207, filed Sep. 23, 2008, Gellerfors et al.263U.S. Appl. No. 60/217,098, filed Jul. 10, 2000, Lannfelt et al.264U.S. Appl. No. 60/621,776, filed Oct. 25, 2004, Lambert et al.265U.S. Appl. No. 60/652,538, filed Feb. 14, 2005, Shughrue et al.266Vickers, "A Vaccine Against Alzheimer's Disease: Developments to Date," Drugs Aging 19(7):487-494, 2002.267Walsh et al., "Amyloid β-Protein Fibrillogenesis. Detection of a Protofibrillar Intermediate," J. Biol. Chem. 272(35):22364-22372, 1997.268Walsh et al., "Amyloid β-Protein Fibrillogenesis. Detection of a Protofibrillar Intermediate," J. Biol. Chem. 272:22364-22372, 1997.269Walsh et al., "Amyloid β-Protein Fibrillogenesis. Structure and Biological Activity of Protofibrillar Intermediates," J. Biol. Chem. 274(35):25945-25952, 1999.270Walsh et al., "Amyloid β-Protein Fibrillogenesis. Structure and Biological Activity of Protofibrillar Intermediates," J. Biol. Chem. 274(36):25945-25952, 1999.271Walsh et al., "Amyloid-β Oligomers: Their Production, Toxicity and Therapeutic Inhibition," Biochem. Soc. Trans. 30:552-7, 2002.272Walsh et al., "Naturally Secreted Oligomers of Amyloid β Protein Potently Inhibit Hippocampal Long-Term Potentiation In Vivo," Nature 416:535-539, 2002.273Walsh et al., "Oligomers on the Brain: The Emerging Role of Soluble Protein Aggregates in Neurodegeneration," Protein Pept. Lett., 11: 213-28, 2004.274Walsh, et al., "Amyloid β-Protein Fibrillogenesis", The Journal of Biological Chemistry, 274:36:25945-25952 (Sep. 3, 1999).275Walsh, et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal in vivo", Nature, 416:535-539 (Apr. 4, 2002).276Ward et al., "Fractionation and Characterization of Oligomeric, Protofibrillar Forms of β-Amyloid Peptide," Biochem. J. 348:137-144, 2000.277Ward, et al., "Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of β-amyloid peptide", Biochem. J., 348:137-144 (2000).278Weidemann et al., "Identification, Biogenesis, and Localization of Precursors of Alzheimer's Disease A4 Amyloid Protein," Cell 57:115-126, 1989.279Weiner et al., "Nasal Administration of Amyloid-β Peptide Decreases Cerebral Amyloid Burden in a Mouse Model of Alzheimer's Disease," Annals Neurol. 48(4):567-579, 2000.280Weiner, et al., "Nasal Administration of Amyloid-β Peptide Decreases Cerebral Amyloid Burden in a Mouse Model of Alzheimer's Disease", Annals. of Neurology, 48:4:567-579 (2000).281Westlind-Danielsson and Arnerup, "Spontaneous In Vitro Formation of Supramolecular β-Amyloid Structures, "βamy Balls", by β-Amyloid 1-40 peptide," Biochemistry 40:14736-43, 2001.282Williams et al., "Structural Properties of Aβ Protofibrils Stabilized by a Small Molecule," Proc. Natl. Acad. Sci. U.S.A. 102(20):7115-20, 2005.283Wirak et al., "Deposits of Amyloid β Protein in the Central Nervous System of Transgenic Mice," Science 253:323-325, 1991.284WO 05/123775 A1, pp. 7-8, published Dec. 29, 2005.285Written Opinion of the International Searching Authority (PCT/SE05/000993), mailed Oct. 4, 2005.286Written Opinion of the International Searching Authority (PCT/SE07/000292), mailed Jul. 20, 2007.287Ye et al., "Protofibrils of Amyloid β-Protein Inhibit Specific K+ Currents in Neocortical Cultures," Neurobiol. Dis. 13:177-190, 2003.288Ye, et al., "Protofibrils of amyloid β-protein inhibit specific K+ currents in neocortical cultures", Neurobiology of Disease, 13:177-190 (2003).289Yoritaka et al., "Immunohistochemical Detection of 4-Hydroxynonenal Protein Adducts in Parkinson Disease," Proc. Natl. Acad. Sci. U.S.A. 93:2696-2701, 1996.290Yoshikai et al., "Genomic Organization of the Human Amyloid Beta-protein Precursor Gene," Gene 87:257-263, 1990.Referenced byCiting PatentFiling datePublication dateApplicantTitleUS8409575Aug 26, 2011Apr 2, 2013Bioarctic Neuroscience AbAntibodies specific for amyloid beta protofibrilUS8613923Jun 12, 2008Dec 24, 2013Ac Immune S.A.Monoclonal antibodyUS8796439Aug 7, 2012Aug 5, 2014Ac Immune S.A.Nucleic acid molecules encoding a humanized antibodyUS8906367 *Jan 7, 2008Dec 9, 2014University Of ZurichMethod of providing disease-specific binding molecules and targetsUS8999936 *Feb 28, 2013Apr 7, 2015Bioarctic Neuroscience AbAntibodies specific for soluble amyloid beta peptide protofibrils and uses thereofUS9034334Aug 26, 2011May 19, 2015Bioarctic Neuroscience AbProtofibril selective antibodies and the use thereofUS9146244Oct 13, 2011Sep 29, 2015Ac Immune S.A.Polynucleotides encoding an anti-beta-amyloid monoclonal antibodyUS9175094Nov 12, 2013Nov 3, 2015Ac Immune S.A.Monoclonal antibodyUS9221900Jul 29, 2011Dec 29, 2015Ac Immune S.A.Methods for identifying safe and functional humanized antibodiesUS20090155249 *Jun 12, 2008Jun 18, 2009Ac Immune S.A.Humanized antibody igg1US20100202968 *Jan 7, 2008Aug 12, 2010University Of ZurichMethod of Providing Disease-Specific Binding Molecules and TargetsUS20100291097 *Oct 3, 2008Nov 18, 2010Andrea PfeiferMonoclonal antibodyUS20100297013 *Oct 3, 2008Nov 25, 2010Andrea PfeiferHumanized antibodyUS20120100129 *Jun 29, 2010Apr 26, 2012Gellerfors PaerN-Terminal Truncated Protofibrils/Oligomers for Use in Therapeutic and Diagnostic Methods for Alzheimer's Disease and Related DisordersUS20130236452 *Feb 28, 2013Sep 12, 2013Bioarctic Neuroscience AbAntibodies specific for soluble amyloid beta peptide protofibrils and uses thereof* Cited by examinerClassifications U.S. Classification530/388.24, 530/387.3, 530/387.1, 530/388.1, 530/387.9, 424/141.1, 424/158.1International ClassificationC07K16/00, C07K14/47, C07K, A61K39/395, A61K39/35, C07K16/18, A61P25/28Cooperative ClassificationC07K2317/24, G01N2800/387, G01N2800/2821, C07K14/4711, C07K16/18European ClassificationC07K16/18, C07K14/47A3Legal EventsDateCodeEventDescriptionDec 20, 2006ASAssignmentOwner name: BIOARTIC NEUROSCIENCE AB, SWEDENFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GELLERFORS, PAR;LANNFELT, LARS;REEL/FRAME:018660/0217Effective date: 20061219Sep 24, 2008ASAssignmentOwner name: BIOARCTIC NEUROSCIENCE AB, SWEDENFree format text: CORRECTIVE ASSIGNMENT TO CORRECT THE MISSPELLING OF ASSIGNEE S NAME (WHICH IS CORRECTLY SPELLED ON THE ATTACHED ASSIGNMENT DATED JANUARY 2007) AND ADDRESS PREVIOUSLY RECORDED ON REEL 018660 FRAME 0217;ASSIGNORS:GELLERFORS, PAR;LANNFELT, LARS;REEL/FRAME:021577/0805Effective date: 20061219Owner name: BIOARCTIC NEUROSCIENCE AB, SWEDENFree format text: CORRECTIVE ASSIGNMENT TO CORRECT THE MISSPELLING OF ASSIGNEE S NAME (WHICH IS CORRECTLY SPELLED ON THE ATTACHED ASSIGNMENT DATED JANUARY 2007) AND ADDRESS PREVIOUSLY RECORDED ON REEL 018660 FRAME 0217. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:GELLERFORS, PAR;LANNFELT, LARS;REEL/FRAME:021577/0805Effective date: 20061219Feb 12, 2013CCCertificate of correctionJul 9, 2015FPAYFee paymentYear of fee payment: 4RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services